However, to date, for patients with advanced or metastatic bladder cancer and alterations in the FGFR2 or FGFR3 gene, targeted therapy based on the inhibitor of FGFR (erdafitinib) is available [15,31,32]. The gene discussed is FGFR2; the disease is urinary bladder carcinoma.